Published in Eur J Pediatr on September 17, 2011
Lupus anticoagulants in two children--bleeding due to nonphospholipid-dependent antiprothrombin antibodies. Eur J Pediatr (2012) 0.97
Duodenal haematoma following endoscopy as a marker of coagulopathy. Pediatr Radiol (2013) 0.80
First-Step Results of Children Presenting with Bleeding Symptoms or Abnormal Coagulation Tests in an Outpatient Clinic. Turk J Haematol (2014) 0.75
Hemarthrosis subtalar, a rare diagnosis. Rev Bras Ortop (2017) 0.75
Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.94
Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med (2007) 6.76
The hemophilias--from royal genes to gene therapy. N Engl J Med (2001) 5.62
Effect of antihemophilic factor on one-stage clotting tests; a presumptive test for hemophilia and a simple one-stage antihemophilic factor assy procedure. J Lab Clin Med (1953) 5.13
WATERFALL SEQUENCE FOR INTRINSIC BLOOD CLOTTING. Science (1964) 3.44
A cell-based model of hemostasis. Thromb Haemost (2001) 2.99
New hemophilia-like disease caused by deficiency of a third plasma thromboplastin factor. Proc Soc Exp Biol Med (1953) 2.57
The rare coagulation disorders--review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia (2004) 1.92
Platelets and thrombin generation. Arterioscler Thromb Vasc Biol (2002) 1.77
Disseminated intravascular coagulation. Crit Care Med (2007) 1.51
Developmental haemostasis. Impact for clinical haemostasis laboratories. Thromb Haemost (2006) 1.44
Scurvy in pediatric patients: a review of 28 cases. J Med Assoc Thai (2003) 1.32
A clinical and medico-social study of haemophilia in Sweden. Acta Med Scand Suppl (1962) 1.16
Factor VII Deficiency. Br J Haematol (2002) 1.10
Vitamin K, an update for the paediatrician. Eur J Pediatr (2008) 1.02
Vitamin K deficiency bleeding in infants and children. Semin Thromb Hemost (1995) 0.99
Congenital alpha(2)-plasmin inhibitor deficiencies: a review. Br J Haematol (2001) 0.96
Combined Factor V and Factor VIII Deficiency. Semin Thromb Hemost (2009) 0.94
Dental surgery in patients with severe factor XI deficiency without plasma replacement. Blood Coagul Fibrinolysis (1992) 0.92
The antifibrinolytic function of factor XIII is exclusively expressed through α₂-antiplasmin cross-linking. Blood (2011) 0.92
Bruising and bleeding in infants and children--a practical approach. Br J Haematol (2006) 0.91
Four cases of bleeding diathesis in children due to congenital plasminogen activator inhibitor-1 deficiency. Haemostasis (1999) 0.84
Factor XI deficiency and its management. Haemophilia (2000) 0.79
Physiology of hemostasis: with relevance to current and future laboratory testing. Clin Lab Med (2009) 0.79
Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation. Crit Care Med (2004) 3.89
Activation of inflammation and coagulation after infusion of C-reactive protein in humans. Circ Res (2005) 2.46
KLF2 provokes a gene expression pattern that establishes functional quiescent differentiation of the endothelium. Blood (2006) 2.41
Role of toll-like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo. Shock (2009) 2.26
Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood (2010) 2.14
Impact of thrombophilia on risk of arterial ischemic stroke or cerebral sinovenous thrombosis in neonates and children: a systematic review and meta-analysis of observational studies. Circulation (2010) 2.12
Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood (2010) 2.04
Hyperglycemia enhances coagulation and reduces neutrophil degranulation, whereas hyperinsulinemia inhibits fibrinolysis during human endotoxemia. Blood (2008) 2.03
Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo. Diabetes (2006) 1.97
Association between thrombotic microangiopathy and reduced ADAMTS13 activity in malignant hypertension. Hypertension (2008) 1.95
Effects on coagulation and fibrinolysis induced by influenza in mice with a reduced capacity to generate activated protein C and a deficiency in plasminogen activator inhibitor type 1. Circ Res (2006) 1.95
Proteomic analysis of high-density lipoprotein. Proteomics (2006) 1.82
Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med (2005) 1.82
β₂-glycoprotein I: a novel component of innate immunity. Blood (2011) 1.75
Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeiden mutation: a randomized trial. Blood (2003) 1.70
Normal to increased thrombin generation in patients undergoing liver transplantation despite prolonged conventional coagulation tests. J Hepatol (2009) 1.65
Crystal structures of TAFI elucidate the inactivation mechanism of activated TAFI: a novel mechanism for enzyme autoregulation. Blood (2008) 1.61
Copy number variation of the activating FCGR2C gene predisposes to idiopathic thrombocytopenic purpura. Blood (2007) 1.60
Cardiovascular risk assessment in haemophilia patients. Thromb Haemost (2010) 1.57
Neurocognitive deficits in children with sickle cell disease: a comprehensive profile. Pediatr Blood Cancer (2010) 1.53
Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: Opposite and synergistic effects of factors XI and XII. Blood (2006) 1.52
Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease. Haematologica (2009) 1.46
Overexpression of activated protein C is detrimental during severe experimental gram-negative sepsis (melioidosis). Crit Care Med (2013) 1.43
Endogenous tissue-type plasminogen activator impairs host defense during severe experimental Gram-negative sepsis (melioidosis)*. Crit Care Med (2012) 1.41
Thrombin-activatable fibrinolysis inhibitor in hypothyroidism and hyperthyroxinaemia. Thromb Haemost (2012) 1.40
The hemostatic status of pediatric recipients of adult liver grafts suggests that plasma levels of hemostatic proteins are not regulated by the liver. Blood (2010) 1.40
Fluid loss does not explain coagulation activation during air travel. Thromb Haemost (2008) 1.38
The receptor for advanced glycation end products impairs host defense in pneumococcal pneumonia. J Immunol (2009) 1.25
Hypercoagulability in the metabolic syndrome. Curr Opin Pharmacol (2005) 1.24
Identification and characterization of Ixodes scapularis antigens that elicit tick immunity using yeast surface display. PLoS One (2011) 1.21
Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood (2010) 1.16
Pentoxifylline reduces fibrin deposition and prolongs survival in neonatal hyperoxic lung injury. J Appl Physiol (1985) (2004) 1.16
Absence of thrombin-activatable fibrinolysis inhibitor protects against sepsis-induced liver injury in mice. J Immunol (2005) 1.16
Circulating nucleosomes and neutrophil activation as risk factors for deep vein thrombosis. Arterioscler Thromb Vasc Biol (2012) 1.14
Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation (2002) 1.13
[Sickle cell disease in heel injection screening. II]. Ned Tijdschr Geneeskd (2009) 1.12
Effects of CRP infusion on endothelial function and coagulation in normocholesterolemic and hypercholesterolemic subjects. J Lipid Res (2007) 1.11
Quality of life of female caregivers of children with sickle cell disease: a survey. Haematologica (2008) 1.11
The hemostatic balance in HIV-infected patients with and without antiretroviral therapy: partial restoration with antiretroviral therapy. AIDS Patient Care STDS (2009) 1.11
Vascular endothelial growth factor in the circulation in cancer patients may not be a relevant biomarker. PLoS One (2011) 1.11
Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood (2004) 1.10
Alterations in lipoprotein homeostasis during human experimental endotoxemia and clinical sepsis. Biochim Biophys Acta (2007) 1.09
Biologic effects of simvastatin in patients with aneurysmal subarachnoid hemorrhage: a double-blind, placebo-controlled randomized trial. J Cereb Blood Flow Metab (2009) 1.08
Diagnosis and management of haemophilia. BMJ (2012) 1.07
Characterization of the H-kininogen-binding site on factor XI: a comparison of factor XI and plasma prekallikrein. J Biol Chem (2001) 1.07
Utility of thromboelastography and/or thromboelastometry in adults with sepsis: a systematic review. Crit Care (2014) 1.04
Acute stress elicited by bungee jumping suppresses human innate immunity. Mol Med (2010) 1.03
Thirty years of hemophilia treatment in the Netherlands, 1972-2001. Blood (2004) 1.03
Markers of inflammation and coagulation indicate a prothrombotic state in HIV-infected patients with long-term use of antiretroviral therapy with or without abacavir. AIDS Res Ther (2010) 1.03
Severe malaria is associated with a deficiency of von Willebrand factor cleaving protease, ADAMTS13. Thromb Haemost (2009) 1.02
Prednisolone dose-dependently influences inflammation and coagulation during human endotoxemia. J Immunol (2007) 1.02
Acute pulmonary embolism in childhood. Thromb Res (2005) 1.01
High-density lipoprotein attenuates inflammation and coagulation response on endotoxin challenge in humans. Arterioscler Thromb Vasc Biol (2007) 1.00
Neurocognitive deficits in children with sickle cell disease are associated with the severity of anemia. Pediatr Blood Cancer (2010) 1.00
The effect of initiating combined antiretroviral therapy on endothelial cell activation and coagulation markers in South African HIV-infected individuals. Thromb Haemost (2010) 1.00
Distribution and kinetics of lipoprotein-bound lipoteichoic acid. Infect Immun (2003) 0.99
Thrombin-activatable fibrinolysis inhibitor binds to Streptococcus pyogenes by interacting with collagen-like proteins A and B. J Biol Chem (2007) 0.99
Alveolar fibrinolytic capacity suppressed by injurious mechanical ventilation. Intensive Care Med (2005) 0.98
Systemic inflammatory response syndrome and compensatory anti-inflammatory response syndrome in sepsis. J Innate Immun (2010) 0.98
Novel 112 kb (epsilonGgammaAgamma) deltabeta-thalassaemia deletion in a Dutch family. Br J Haematol (2003) 0.96
Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood (2013) 0.96
Urokinase receptor is necessary for bacterial defense against pneumonia-derived septic melioidosis by facilitating phagocytosis. J Immunol (2010) 0.96
Factor Xa activation of factor V is of paramount importance in initiating the coagulation system: lessons from a tick salivary protein. Circulation (2013) 0.95
Activated factor V is a cofactor for the activation of factor XI by thrombin in plasma. Proc Natl Acad Sci U S A (2010) 0.95
Paediatric anticoagulation guidelines. S Afr Med J (2012) 0.95
Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets. Blood (2003) 0.94
An unbalance between von Willebrand factor and ADAMTS13 in acute liver failure: implications for hemostasis and clinical outcome. Hepatology (2013) 0.94
BH3-only protein Noxa regulates apoptosis in activated B cells and controls high-affinity antibody formation. Blood (2011) 0.94
Chronic pulmonary embolism in Klippel-Trenaunay syndrome. J Am Acad Dermatol (2011) 0.94
Blood transfusion during cardiac surgery is associated with inflammation and coagulation in the lung: a case control study. Crit Care (2011) 0.93
Activation of TAFI on the surface of Streptococcus pyogenes evokes inflammatory reactions by modulating the kallikrein/kinin system. J Innate Immun (2008) 0.93
Platelets in patients with premature coronary artery disease exhibit upregulation of miRNA340* and miRNA624*. PLoS One (2011) 0.93
The antibacterial activity of peptides derived from human beta-2 glycoprotein I is inhibited by protein H and M1 protein from Streptococcus pyogenes. Mol Microbiol (2007) 0.93
Dominant factor XI deficiency caused by mutations in the factor XI catalytic domain. Blood (2004) 0.91
Nur77 modulates hepatic lipid metabolism through suppression of SREBP1c activity. Biochem Biophys Res Commun (2007) 0.90
Protein C inhibitor--a novel antimicrobial agent. PLoS Pathog (2009) 0.90
Behavioral and emotional problems in children with sickle cell disease and healthy siblings: Multiple informants, multiple measures. Pediatr Blood Cancer (2009) 0.89
Evolutionary conservation of the lipopolysaccharide binding site of β₂-glycoprotein I. Thromb Haemost (2011) 0.89
Analysis of blood coagulation in mice: pre-analytical conditions and evaluation of a home-made assay for thrombin-antithrombin complexes. Thromb J (2005) 0.88
Social participation of patients with hemophilia in the Netherlands. Blood (2007) 0.88
Enhanced coagulation activation in preeclampsia: the role of APC resistance, microparticles and other plasma constituents. Thromb Haemost (2002) 0.87
Amyloid endostatin induces endothelial cell detachment by stimulation of the plasminogen activation system. Mol Cancer Res (2003) 0.87
Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. Blood (2002) 0.87
Plasmin-mediated activation and inactivation of thrombin-activatable fibrinolysis inhibitor. Biochemistry (2002) 0.87
VEGF levels in plasma in relation to platelet activation, glycemic control, and microvascular complications in type 1 diabetes. Diabetes Care (2013) 0.86
Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice are susceptible to intracerebral thrombosis and ischemic stroke. PLoS One (2010) 0.86
Platelet-activating factor receptor contributes to host defense against Pseudomonas aeruginosa pneumonia but is not essential for the accompanying inflammatory and procoagulant response. J Immunol (2008) 0.86
Diabetes does not influence activation of coagulation, fibrinolysis or anticoagulant pathways in Gram-negative sepsis (melioidosis). Thromb Haemost (2011) 0.85
Effects of IC14, an anti-CD14 antibody, on coagulation and fibrinolysis during low-grade endotoxemia in humans. J Infect Dis (2002) 0.85
Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers. Br J Haematol (2004) 0.85
Venous thromboembolic disease in childhood. Semin Thromb Hemost (2003) 0.85
Anticoagulation beyond direct thrombin and factor Xa inhibitors: indications for targeting the intrinsic pathway? Thromb Haemost (2013) 0.84
The risk of postthrombotic syndrome in children with congenital heart disease. J Pediatr (2002) 0.84
Development and validation of a pediatric severity index for sickle cell patients. Am J Hematol (2010) 0.84
Pharmacokinetics and pharmacodynamics of danaparoid during continuous venovenous hemofiltration: a pilot study. Crit Care (2007) 0.84
Endogenous α2-antiplasmin is protective during severe gram-negative sepsis (melioidosis). Am J Respir Crit Care Med (2013) 0.84
Plasminogen activator inhibitor-1 regulates neutrophil influx during acute pyelonephritis. Kidney Int (2008) 0.83